Call for Papers

Special Delivery: Targeting and Delivering RNA-based therapeutics


Guest Editors:

Steven F Dowdy, UCSD
Matthew Levy, Albert Einstein College of Medicine

RNA-based therapeutics, including siRNAs, miRNAs, Anti-Sense Oligonucleotides (ASOs), Aptamers, synthetic mRNA and CRISPR-Cas9, have the potential to target the extensive undruggable genome. However, to reach their full potential, they first need to access the cellular machinery, ensconced within the billion-year-old lipid bilayer. Cellular uptake of cargos does not equate to entry into the cytoplasm and nucleus of a cell. Consequently, overcoming the lipid bilayer to deliver these RNA macromolecules into cells remains the major problem in advancing RNA therapeutics based on these technologies. In recent years, significant advances in the delivery of RNA-based therapeutics have begun to be realized. There are now two FDA approved antisense-based RNA drugs and multiple clinical trials involving siRNAs and mRNAs.

This special issue of Nucleic Acids Therapeutics will provide insight and an update on the current status of RNA-based therapeutics with a focus on delivery - getting these therapeutic cargoes to their intracellular targets and more importantly, into cells.


Please submit rigorous studies that include appropriate controls for consideration for this special issue if you have work describing advances in:

  • The delivery of siRNAs, miRNAs, antisense oligonucleotides (ASOs), aptamers, synthetic mRNA and CRISPR—Cas9
  • Mechanisms or methods to enhance the delivery of RNA-based therapeutics

Benefits of publishing include:

  • Rapid, high-quality peer review
  • Open access options available
  • Fast and user-friendly electronic submission
  • Maximum exposure: accessible in 170 countries worldwide

Learn More about this journal

Deadline for Manuscript Submission:
December 15, 2017

SUBMIT YOUR
MANUSCRIPT